Domestic Collaboration Milestone: QX004N Enters Phase III Trial for Psoriasis, Triggering RMB 58 Million Payment

Note:This article does not constitute any investment opinions or suggestions., subject to official/company announcements;This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted requires authorization.

PharmaCircleMonitoring shows that: recently, Jiangsu Quanxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Quanxin Biopharmaceutical" or "the Company", 2509.HK) and Hansoh PharmaPharmaceutical GroupHansoh Pharma (3692.HK) and Qybio jointly developed QX004N / HS-20137 has entered the Phase III clinical trial stage for psoriasis (Psoriasis, Ps), becoming the fourth product in Qybio's pipeline to successfully advance to Phase III clinical trials.The company has received a total of RMB 58 million from Hansoh Pharma as payment for the Ps III milestone and other payments under the licensing agreement.。

In April 2024, Quanxin Biotech entered into an exclusive licensing agreement with Hansoh (Shanghai) Health Technology Co., Ltd., a wholly-owned subsidiary of Hansoh Pharma, for the development, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macao.

QX004N Injection (Sample Image)

QX004N is a recombinant humanized IgG1 monoclonal antibody that specifically binds to human IL-23. By specifically binding to the p19 subunit of human IL-23, it blocks the interaction between extracellular IL-23 and the IL-23 receptor on the cell surface, inhibiting the release of pro-inflammatory cytokines and chemokines mediated by IL-23, thereby achieving therapeutic effects.